MA44484A - Biomarqueurs de protéinopathies et utilisations associées - Google Patents

Biomarqueurs de protéinopathies et utilisations associées

Info

Publication number
MA44484A
MA44484A MA044484A MA44484A MA44484A MA 44484 A MA44484 A MA 44484A MA 044484 A MA044484 A MA 044484A MA 44484 A MA44484 A MA 44484A MA 44484 A MA44484 A MA 44484A
Authority
MA
Morocco
Prior art keywords
proteinopathy
biomarkers
associated uses
proteinopathy biomarkers
Prior art date
Application number
MA044484A
Other languages
English (en)
Inventor
Sergio Pablo Sardi
Clemens Scherzer
Original Assignee
Genzyme Corp
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Brigham & Womens Hospital Inc filed Critical Genzyme Corp
Publication of MA44484A publication Critical patent/MA44484A/fr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08Sphingolipids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
MA044484A 2016-03-25 2017-03-24 Biomarqueurs de protéinopathies et utilisations associées MA44484A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662313638P 2016-03-25 2016-03-25
US201662372523P 2016-08-09 2016-08-09

Publications (1)

Publication Number Publication Date
MA44484A true MA44484A (fr) 2019-01-30

Family

ID=58547821

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044484A MA44484A (fr) 2016-03-25 2017-03-24 Biomarqueurs de protéinopathies et utilisations associées

Country Status (10)

Country Link
US (1) US20200124624A1 (fr)
EP (1) EP3433623A2 (fr)
JP (2) JP6940515B2 (fr)
KR (1) KR20180124971A (fr)
AU (1) AU2017238769A1 (fr)
CA (1) CA3018745A1 (fr)
IL (1) IL261906A (fr)
MA (1) MA44484A (fr)
MX (1) MX2018011679A (fr)
WO (1) WO2017165766A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
SG11202108502UA (en) 2019-02-04 2021-09-29 Freeline Therapeutics Ltd Polynucleotides
WO2021173962A1 (fr) * 2020-02-28 2021-09-02 Genemo, Inc. Méthodes et matériaux pour le diagnostic et le traitement d'un trouble neuronal
CN116420078A (zh) * 2020-10-14 2023-07-11 戴纳立制药公司 用于治疗和监测额颞痴呆的方法
CN112798727B (zh) * 2021-04-09 2021-07-06 宝枫生物科技(北京)有限公司 用于诊断脑白质病变的生物标志物f7及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8781557B2 (en) 1999-08-11 2014-07-15 Osteoplastics, Llc Producing a three dimensional model of an implant
WO2001097829A2 (fr) * 2000-06-19 2001-12-27 Genzyme Corporation Traitement de substitution enzymatique, therapie genique et therapie par petites molecules pour maladies liees au stockage lysosomal
WO2005080594A2 (fr) 2004-02-24 2005-09-01 Innogenetics N.V. Methode de determination des risques qu'a un sujet de contracter une maladie neurologique
GB2414309B (en) 2004-05-18 2009-02-25 Simon Richard Daniel Spherical display and control device
US20080248512A1 (en) 2006-09-12 2008-10-09 Genzyme Corporation Methods for detection of lysosomal storage disease
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
EP2361089A4 (fr) * 2008-11-14 2012-08-22 Parkinson S Inst Compositions et procédés pour le traitement d une fonction altérée de l' -synucléine
EP2596133A4 (fr) * 2010-07-23 2014-04-23 Harvard College Méthodes de dépistage de maladies ou d'affections neurologiques ou neuropsychiatriques
MY173998A (en) 2011-03-18 2020-03-03 Genzyme Corp Glucosylceramide synthase inhibitors
CN103764166B (zh) * 2011-06-22 2017-10-24 通用医疗公司 蛋白质病的治疗
WO2013070953A1 (fr) 2011-11-08 2013-05-16 University Of Washington Procédés et compositions d'analyse d'enzymes lysosomales

Also Published As

Publication number Publication date
CA3018745A1 (fr) 2017-09-28
IL261906A (en) 2018-10-31
KR20180124971A (ko) 2018-11-21
JP2019513231A (ja) 2019-05-23
MX2018011679A (es) 2019-06-24
JP6940515B2 (ja) 2021-09-29
JP7250081B2 (ja) 2023-03-31
JP2021185377A (ja) 2021-12-09
EP3433623A2 (fr) 2019-01-30
US20200124624A1 (en) 2020-04-23
WO2017165766A2 (fr) 2017-09-28
AU2017238769A1 (en) 2018-11-15
WO2017165766A3 (fr) 2017-11-02

Similar Documents

Publication Publication Date Title
MA50502A (fr) Adénovirus et utilisations associées
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
PT3667980T (pt) Indicar e receber localização de recurso
MA46700A (fr) Variants polypeptidiques et ses utilisations
EP3356558A4 (fr) Biomarqueurs pathogènes et utilisations associées
MA50618A (fr) Polyrhérapies et leurs utilisations
EP3453214A4 (fr) Agencement de ressources
EP3365686A4 (fr) Sondes réactives à la cystéine et utilisations associées
EP3408402A4 (fr) Détection magnéto-électrochimique
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
EP3509589A4 (fr) Nouvelles utilisations
EP3341387A4 (fr) Inhibiteurs de sialyltransférase et utilisations de ceux-ci
EP3538261A4 (fr) Catalyseurs en pérovskite et leurs utilisations
EP3350181A4 (fr) Ligands her3 et utilisations de ceux-ci
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations
EP3517118A4 (fr) Activateur de sperme et utilisations associées
MA43957A (fr) Biomarqueurs de copanlisib
EP3450444A4 (fr) Composés de type crocine et utilisations correspondantes
MA41022A (fr) Ciblage lysosomial et utilisations correspondantes
MA43958A (fr) Biomarqueurs copanlisib
EP3402879A4 (fr) Lubrifiant modifié
EP3459937A4 (fr) Dérivé de thiazole et utilisations
EP3665994A4 (fr) Définition de ressources
PT3365321T (pt) Zwiterião de solabegron e suas utilizações
PT3337506T (pt) Combinações e suas utilizações